Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

DNA test could Fine-Tune blood thinners for heart patients

NCT ID NCT06143709

Knowledge-focused Sponsor: University of Florida Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 19, 2026 · Updated 2 times

Summary

This registry studies how genetic information can help doctors choose the best antiplatelet medication for people who have had a heart stent procedure. Over 1,600 participants will provide DNA samples and be followed for 12 months to track heart events and bleeding. The goal is to learn how to personalize therapy based on genetics and other patient factors.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
DNA sample collection
What this could lead to
If successful, this could help doctors personalize antiplatelet medications based on a patient's genetics, potentially reducing heart attacks and strokes while minimizing bleeding risks.
What could go wrong
This is an observational registry, not a treatment trial, so it won't directly test a new drug or therapy. Results may not lead to immediate changes in clinical practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

1,643 people

The number who actually took part.

Started

Jul 2020

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The target patient population will be male or female adults (age 18 years), of any race or ethnicity, who undergo PCI and clinical CYP2C19 genotyping, and are treated with clopidogrel, prasugrel, or ticagrelor in addition to aspirin.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria * Age ≥18 years * Underwent percutaneous coronary intervention for any indication * Had clinical CYP2C19 genotyping * Treated with dual antiplatelet therapy including clopidogrel, prasugrel, or ticagrelor plus aspirin or * Treated with a combination of a P2Y12 inhibitor i.e. clopidogrel, prasugrel or ticagrelor plus an oral anticoagulant. Exclusion Criteria: * Managed surgically * Treated with thrombolysis within 48 hours

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Coronary artery disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

coronary artery disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Coronary artery disease Percutaneous coronary intervention

Contacts and locations

Locations

  • University of Florida

    Gainesville, Florida, 32609, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.